The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

Understanding the type of arthritis, its causes, and management options is the first step toward living well with the condition.

In phase 3 clinical trials, tildrakizumab treatment was associated with significantly higher ACR20 response rates at week 24 compared with placebo.

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced that the US ...

Ilumya has secured marketing authorisations from more than 55 health authorities worldwide.

The manufacturer of the interleukin-23 inhibitor tildrakizumab (Ilumya), Sun Pharma, announced today that the FDA has ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...

—In a study of more than 600 psoriatic arthritis (PsA) patients conducted in a real-world setting, investigators recently sought to identify phenotype clusters and how they’re associated with patients ...

A Prescription Drug User Fee Act target date of March 6, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...